Search Results

Jacobs was selected by FUJIFILM Diosynth Biotechnologies to support delivery of $1.2 billion expansion of an end-to-end, large-scale cell culture contract manufacturing site in Holly Springs, North Carolina.

VolitionRx Limited has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd, a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis Therapeutics.

Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics, Inc. announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.

The global contract development and manufacturing organization is investing $1.2 billion to boost production capabilities at its Holly Springs, North Carolina, site including mammalian cell culture bioreactors.

FUJIFILM Irvine Scientific, Inc. announced the addition of the Life Whisperer Genetics module to its Life Whisperer software package 1, enabling non-invasive evaluation of embryo genetic integrity during in vitro fertilization.

PhenoVista Biosciences, a contract research organization and leading provider of both custom and off-the-shelf, imaging-based assay services based in San Diego, California, announced a strategic investment by FUJIFILM Corporation, Tokyo.